John G. Ullman & Associates’s AbbVie ABBV Stock Holding History

John G. Ullman & Associates’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$274K	Buy	1,088 +10	+0.9%	+$2.15K	0.03%	165
2026 Q1	$234K	Buy	1,078 +23	+2%	+$5.1K	0.03%	163
2025 Q4	$241K	Hold	1,055	–	–	0.03%	165
2025 Q3	$244K	Buy	+1,055	New	+$215K	0.03%	159
2024 Q2	–	Sell	-1,220	Closed	-$222K	–	180
2024 Q1	$222K	Buy	+1,220	New	+$210K	0.03%	165
2023 Q2	–	Sell	-1,479	Closed	-$236K	–	178
2023 Q1	$236K	Buy	+1,479	New	+$226K	0.04%	160

Other funds holding ABBV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

John G. Ullman & Associates's ABBV Position: Q2 2026 in Review

John G. Ullman & Associates increased its AbbVie (ABBV) stake by 0.93% in Q2 2026, buying an estimated $2.15K and bringing the position to 1,088 shares worth $274K. The position accounts for 0.03% of the portfolio, ranked #165.

John G. Ullman & Associates first reported a position in ABBV in Q1 2023 and has held it in 6 quarters since. 4,192 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

John G. Ullman & Associates held 1,088 shares of AbbVie worth $274K as of Q2 2026.
John G. Ullman & Associates bought 10 AbbVie shares in Q2 2026, an estimated $2.15K.
AbbVie made up 0.03% of John G. Ullman & Associates's portfolio in Q2 2026, its #165 holding.
John G. Ullman & Associates first reported a position in AbbVie in Q1 2023 and has held it in 6 quarters since.
4,192 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on John G. Ullman & Associates's 13F filing for Q2 2026, filed 11 Aug 2026.